EVOFEM BIOSCIENCE INC - EVFM STOCK NEWS

Evofem Biosciences (NASDAQ: EVFM) reported financial results for Q3 2020, marking its first product sales of $0.3 million from the launch of Phexxi, a hormone-free contraceptive gel. Total operating expenses rose to $26.4 million, leading to a net loss of $29.9 million, or $(0.37) per share. The company secured a $25 million strategic investment from Adjuvant Capital to fund ongoing clinical trials and expand market access. Evofem initiated the EVOGUARD Phase 3 trial for EVO100, aimed at preventing chlamydia and gonorrhea infections in women.

Evofem Biosciences, Inc. (NASDAQ: EVFM) will host a webcast and conference call on November 9, 2020, at 5:00 p.m. ET to discuss its third quarter 2020 financial results and business highlights. Interested parties can access the live webcast and related presentation on the Company's Investor page. Dial-in numbers for participation include (866) 503-5561 (U.S. toll-free) and (253) 336-2965. A telephone replay will be available shortly after the call through November 12, 2020, using conference ID 2639368.

Evofem Biosciences (NASDAQ: EVFM) will participate in a Virtual Investor KOL Roundtable on October 29, 2020, at 2:00 p.m. ET. CEO Saundra Pelletier and CMO Kelly Culwell will discuss women's reproductive health alongside expert Patricia Cason, RN, MS, FNP-BC. The event will delve into the current birth control landscape and contraceptive counseling. A live webcast will be available, with a replay accessible for three months.

Evofem Biosciences, Inc. (NASDAQ: EVFM) has commenced the pivotal Phase 3 EVOGUARD trial, enrolling its first patient to assess the efficacy and safety of EVO100 in preventing urogenital chlamydia and gonorrhea in women. With rising infection rates and increasing antibiotic resistance, the need for preventive measures like EVO100 has become critical. The trial will involve 1,730 women at risk of these infections. The FDA has granted EVO100 Fast Track Designation for chlamydia prevention, and it has also received Qualified Infectious Disease Product designation for gonorrhea.

Evofem Biosciences (NASDAQ: EVFM) has secured $25 million from the sale of unsecured convertible promissory notes to Adjuvant Capital. The notes, convertible at a price of $3.65 per share, will fund the upcoming Phase 3 clinical trial, EVOGUARD, for its product EVO100 targeting urogenital chlamydia and gonorrhea prevention in women. The company aims to expand market access for its non-hormonal contraceptive, Phexxi™, approved in May 2020. This partnership aligns with Adjuvant's mission to enhance contraceptive access globally.

Evofem Biosciences (NASDAQ: EVFM) announced new clinical trial data on Phexxi™ and EVO100 to be presented at major medical society meetings this October. The data includes insights into Phexxi users and factors affecting reinfection rates of chlamydia and gonorrhea, as well as findings related to the sexual impact of treatment. The AMPREVENCE trial enrolled 860 women, while the AMPOWER trial involved 1,384 participants, evaluating Phexxi's contraceptive efficacy. The company continues its publication strategy with nine abstracts to be presented this fall.

Evofem Biosciences, Inc. (NASDAQ: EVFM) announced a rescheduled virtual fireside chat at the 2020 Cantor Global Virtual Healthcare Conference, set for September 17, 2020, from 1:20 p.m. to 1:50 p.m. ET. Interested parties can access the live and archived webcast on Evofem's website under the Investors section. The company focuses on developing innovative products in women's sexual and reproductive health, including its first product, Phexxi™, a hormone-free contraceptive gel. The firm is also advancing EVO100 into a Phase 3 clinical trial for STI prevention.

Evofem Biosciences (NASDAQ: EVFM) announced positive results from its Phase 2b AMPREVENCE trial at the 2020 STD Prevention Virtual Conference. The trial evaluated EVO100 for preventing urogenital chlamydia and gonorrhea in women, achieving a 50% risk reduction for chlamydia and 78% for gonorrhea compared to placebo. The product was well tolerated by participants. Following this success and a favorable FDA data review, Evofem plans to initiate a Phase 3 trial in Q4 2020, demonstrating the potential impact of EVO100 on women's health amid rising STI rates in the U.S.

Evofem Biosciences (NASDAQ: EVFM) announced the U.S. launch of Phexxi™, the first non-hormonal prescription vaginal gel for on-demand contraception. Approved by the FDA on May 22, 2020, Phexxi maintains vaginal pH to prevent sperm viability. The product will be marketed in boxes of 12 applicators. Evofem also introduced the Phexxi Concierge Experience, a telemedicine support system for prescription access and counseling. Financial assistance will allow eligible women to purchase Phexxi with low co-pays. Notably, Phexxi does not prevent STIs and may have side effects.